 "Sun Pharma falls; US cancer drug supply contract may end")
Shares in Sun Pharmaceutical Industries fell 1.6 percent on worries the drug maker will soon see an end to its temporary arrangement to supply cancer drug Doxil in the United States.
Janssen Biotech, a unit of Johnson & Johnson’s , said on Monday it would resume supplies of 20 mg dosages of Doxil, which treats ovarian and other cancers. The US healthcare firm had suspended supplies following the manufacturing disruption from a third party supplier.
[caption id=“attachment_495032” align=“alignleft” width=“380”]  Agencies[/caption]
Sun Pharma had been supplying Doxil in the United States under a temporary arrangement with the Food and Drug Administration.
Brokerage Edelweiss has estimated Sun’s US sales of Doxil had reached around $110-120 million, with 90-95 percent EBITDA margins, during the temporary period.
“Though this opportunity was short term and the resumption was anticipated by end 2012, the timing of the same was uncertain. Nevertheless, this ends a lucrative short term opportunity for Sun,” Edelweiss said in a email to clients.
Sun Pharma declined to comment.
Reuters
 "Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty")
 "Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched")
 "Who is CP Radhakrishnan, India's next vice-president?")
 "Israel informed US ahead of strikes on Hamas leaders in Doha, says White House")
 "Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty")
 "Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched")
 "Who is CP Radhakrishnan, India's next vice-president?")
 "Israel informed US ahead of strikes on Hamas leaders in Doha, says White House")
](https://images.firstpost.com/wp-content/uploads/2012/10/drugs-agencies5.jpg){kind=link}